

(FINAL/APPROVED)

VIRGINIA BOARD OF PHARMACY

PUBLIC HEARING FOR REVISION TO SCHEDULING TO CONFORM TO DEA DE-SCHEDULING FOR EPIDIOLEX

December 10, 2020
Virtual Meeting

Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233-1463

CALL TO ORDER: The public hearing was called to order at 9:07a.m.

PRESIDING: Kristopher Ratliff, Chairman

MEMBERS PRESENT: Cheryl Nelson, Vice Chairman
Glen Bolyard
James L. Jenkins, Jr.
Ryan Logan
Patricia Richards-Spruill
William Lee
Sarah Melton
Dale St. Clair
Bernard Henderson

STAFF PRESENT: Caroline D. Juran, Executive Director (On-Site)
Ellen B. Shinaberry, Deputy Executive Director
James Johnson, Deputy Executive Director
Annette Kelley, Deputy Executive Director
Beth O' Halloran, Deputy Executive Director
Elaine Yeatts, Senior Policy Analyst, DHP (On-Site)
David E. Brown, D.C., Director, DHP
Barbara Allison-Bryan, M.D., Chief Deputy, DHP
James Rutkowski, Assistant Attorney General
Melody Morton, Inspection Manager, DHP
Kiara Christian, Executive Assistant

CALL FOR PUBLIC COMMENT: Mr. Ratliff noted that to conform the Drug Control Act to recent changes enacted by the Drug Enforcement Administration, the board will consider:

- Deleting #4 from 18VAC110-20-323 which will remove cannabidiol from Schedule V and by default, place it into Schedule VI.

The revision action would remain into effect permanently, unless otherwise amended.

PUBLIC COMMENT: Jan Burrows, State Government Affairs Director, Greenwich BioScience, offered support of removing Epidiolex from Schedule V in accordance with Federal Law.

Dillon Bishop, Cannabiz Business Association, offered support of de-scheduling Epidiolex.

ADJOURN:

The public hearing adjourned at 9:16am.

 DPH

Kristopher Ratliff, Chairman



Caroline D. Juran, Executive Director

3-30-21

Date

3/30/2021

Date